{{Rsnum
|rsid=17731538
|Gene=ABCG2
|Chromosome=4
|position=88134227
|Orientation=plus
|GMAF=0.1194
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ABCG2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 6.2 | 34.5 | 59.3
| HCB | 0.7 | 10.9 | 88.3
| JPT | 2.7 | 22.1 | 75.2
| YRI | 0.0 | 4.8 | 95.2
| ASW | 0.0 | 12.3 | 87.7
| CHB | 0.7 | 10.9 | 88.3
| CHD | 0.0 | 13.8 | 86.2
| GIH | 0.0 | 13.9 | 86.1
| LWK | 0.9 | 6.4 | 92.7
| MEX | 1.7 | 19.0 | 79.3
| MKK | 0.0 | 20.5 | 79.5
| TSI | 5.9 | 40.2 | 53.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17731538
|Name_s=
|Gene_s=ABCG2
|Feature=Intron
|Evidence=PubMed ID:18256692
|Annotation=SNP is associated with clinical reponse to methotrexate in patients with psoriasis.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Psoriasis
|Curation Level=Curated
|PharmGKB Accession ID=PA161149200
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17731538
|overall_frequency_n=19
|overall_frequency_d=128
|overall_frequency=0.148438
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}